Evidence map›Paper›PMID 30758659›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2019

Contribution of Nitric oxide synthase 3 genetic variants to nasopharyngeal carcinoma risk and progression in a Tunisian population.

Sahar Aouf, Ala Laribi, Sallouha Gabbouj, Elham Hassen, Noureddine Bouaouinaa, Abdelfattah Zakhama, Hedi Harizi

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Human glutathione peroxidase codon 198 variant increases nasopharyngeal carcinoma risk and progression.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sahar AoufLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Ala LaribiLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Sallouha GabboujLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Elham HassenLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Noureddine BouaouinaaLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Abdelfattah ZakhamaLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia.
Hedi HariziLaboratory of Molecular Immuno-Oncology, Faculty of Medicine of Monastir, University of Monastir, 5019, Monastir, Tunisia. hharizi@hotmail.fr.ORCID http://orcid.org/0000-0003-3856-3311
University of Monastir · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe conduct this study to evaluate the clinical and functional impact of Nitric Oxide Synthase 3 (NOS3) T-786C and G894T genetic variants on nasopharyngeal carcinoma (NPC) risk and progression in a Tunisian population.

methods259 NPC patients and 169 healthy controls were enrolled into our case-control study. Blood samples were genotyped by the RFLP-PCR analysis. The levels of Nitric oxide (NO) were measured by a colorimetric assay kit in the plasma of NPC patients, healthy controls and according to NOS3 genotypes. The correlation between the NOS3 variants and the clinicopathological parameters was examined.

resultsWe found no linkage disequilibrium between NOS3 T-786C and G894T variants. These results showed that NOS3 variants were genetically independent. In contrast to NOS3 T-786C, a significant association was found between NOS3 G894T polymorphism and NPC risk. The 894T allele decreased significantly in NPC patients and appeared as protective factor (OR = 0.65, CI 95%= 0.48-0.88, p = 0.006). NPC patients had significantly higher levels of plasma NO as compared to healthy controls (p = 0.0011). The T-786C mutation reduced the levels of plasma NO and decreased risk of lymph node metastasis in NPC patients (OR = 0.64, 95% CI = 0.43-0.96; p = 0.03). In contrast, NOS3 G894T polymorphism had no effects neither on NO plasma levels nor clinical parameters.

conclusionsThis is the first study to associate NPC with significantly higher levels of plasma NO. NOS3-derived NO could play key roles in NPC pathogenesis. NOS3 variants differently contribute to NPC risk and progression in a Tunisian population. NOS3 G894T was associated with NPC risk. NOS3 T-786C decreased the levels of plasma NO and reduced the development of regional lymph node metastasis.

Indexed as

AdolescentAdultAgedAged, 80 and overAllelesCase-Control StudiesChildFemaleGenotypeHumansMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNitric OxideNitric Oxide Synthase Type IIINitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanClinical parametersNasopharyngeal carcinomaNOS3 genePlasma NOPolymorphisms

Identifiers

PMID30758659
OpenAlexW2913288085

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.